Keywords: Merck & Co, Vorapaxar, Cardiovascular events, Bleeding, Blood thinner, Anti-thrombotic

Study shows vorapaxar reduces cardiovascular events, but raises bleeding worries

Article | 26 March 2012

Print This

Confirming earlier mixed top-line results, US drug giant Merck & Co (NYSE: MRK; The Pharma Letter February 8) presented results from ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in